Accretion Pharmaceuticals Ltd
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]
- Market Cap ₹ 229 Cr.
- Current Price ₹ 206
- High / Low ₹ 220 / 54.6
- Stock P/E 17.4
- Book Value ₹ 56.6
- Dividend Yield 0.00 %
- ROCE 28.9 %
- ROE 27.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| 13 | 57 | 90 | 101 | |
| Sales growth | +330% | +56% | +22% | |
| 11 | 45 | 75 | 81 | |
| Operating Profit | 3 | 12 | 15 | 20 |
| OPM % | 19% | 21% | 17% | 20% |
| 0 | 0 | 0 | 0 | |
| Interest | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 1 | 1 | 2 |
| Profit before tax | 2 | 10 | 13 | 18 |
| Tax % | 25% | 30% | 26% | |
| 1 | 7 | 10 | 13 | |
| EPS in Rs | 1.96 | 8.31 | 8.70 | 11.81 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 263% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| Last Year: | 28% |
Balance Sheet
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|
| Equity Capital | 4 | 8 | 11 | 11 |
| Reserves | 1 | 7 | 44 | 52 |
| 13 | 14 | 12 | 17 | |
| 8 | 10 | 10 | 8 | |
| Total Liabilities | 27 | 40 | 77 | 87 |
| 5 | 6 | 13 | 13 | |
| CWIP | 0 | 0 | 0 | 2 |
| Investments | 0 | 0 | 0 | 0 |
| 22 | 34 | 63 | 72 | |
| Total Assets | 27 | 40 | 77 | 87 |
Cash Flows
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -12 | -1 | -15 | |
| -5 | -2 | -9 | |
| 17 | 2 | 27 | |
| Net Cash Flow | 0 | -0 | 4 |
| Free Cash Flow | -17 | -2 | -23 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -479% | 18% | -75% |
Ratios
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 159 | 74 | 91 |
| Inventory Days | 564 | 188 | 159 |
| Days Payable | 256 | 69 | 32 |
| Cash Conversion Cycle | 466 | 193 | 218 |
| Working Capital Days | 189 | 65 | 145 |
| ROCE % | 46% | 29% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Direct Export Revenue Share % |
|
||||
| Capacity Utilization - Capsules % |
|||||
| Capacity Utilization - External Preparations % |
|||||
| Capacity Utilization - Oral Liquid % |
|||||
| Capacity Utilization - Oral Powder % |
|||||
| Capacity Utilization - Tablets % |
|||||
| Sales on Contract Manufacturing / Loan License Revenue Share % |
|||||
| Top 10 Customer Revenue Concentration % |
|||||
Extracted by Screener AI
Documents
Announcements
-
Investor Presentation
- Investor presentation for half-year ended 30 September 2026 uploaded on company website.
-
Outcome of Board Meeting
- Board approved H1 FY2026 unaudited results: revenue ₹55.04 crore, profit ₹8.20 crore.
-
Press Release
- Accretion Pharmaceuticals reported H1 FY27 revenue of ₹55.04 crore, PAT of ₹8.20 crore, and stronger export growth.
-
Outcome of Board Meeting
- Board approved H1 FY2026 unaudited results; revenue 5,504.10 lakh, profit 820.14 lakh.
-
Shareholders meeting
- Revised postal ballot results: five special resolutions passed, including borrowing limit increase and charge creation.
Annual reports
-
Annual Report 2026
from nse
-
Annual Report 2025
from nse
-
Annual Report 2025
from web
Concalls
-
Nov 2026PPT
-
May 2026PPT
-
Nov 2025Transcript PPT REC
Business Profile[1]
The company manufactures pharmaceutical formulations, including both generic and branded products. It offers contract and third-party manufacturing services for domestic and international markets. Its clientele includes private institutions, government sectors (state and central), and reputed pharmaceutical companies.